Calcineurin expression, activation, and function in cardiac pressure- overload hypertrophy

Circulation

Volumn 101, Issue 20, 2000, Pages 2431-2437

  Lim, Hae W ^b   De Windt, Leon J ^b   Steinberg, Leonard ^b   Taigen, Tyler ^b   Witt, Sandra A ^b   Kimball, Thomas R ^b   Molkentin, Jeffery D ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

Aorta; Hypertrophy; Pressure

Indexed keywords

CALCINEURIN; CALMODULIN; CYCLOSPORIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CLAMPING; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HYPERTENSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0034705070     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.20.2431     Document Type: Article

References (35)

1. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;55:56-64.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med. 1990;322:1561-1566.
3. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Ann Rev Physiol. 1997;59:551-571.
4. Vikstrom KL, Leinwand LA. Contractile protein mutations and heart disease. Curr Opin Cell Biol. 1996;8:97-105.
5. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi Y, Mizuno T, Maemura K, Kurihara H, Aikawa R, Takano H, Yazaki Y. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem. 1996;271:3221-3228.
6. Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. J Biol Chem. 1997; 272:5783-5791.
7. Bhat GJ, Abraham ST, Baker KM. Angiotensin II interferes with interleukin 6-induced Stat3 signaling by a pathway involving mitogen-activated protein kinase kinase 1. J Biol Chem. 1996;271:22447-22452.
8. Ramirez MT, Sah VP, Zhao XL, Hunter JJ, Chien KR, Brown JH. The MEKK-JNK pathway is stimulated by alpha 1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J Biol Chem. 1997;272:14057-14061.
9. Kudoh S, Komuro I, Mizuno T, Yamazaki T, Zou Y, Shiojima I, Takekoshi N, Yazaki Y. Angiotensin II stimulates c-jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res. 1997;80: 139-146.
10. Sadoshima J, Izumo S. Molecular characterization of angiotensin Il-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res. 1993;73:413-423.
11. Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Circ Res. 1993;73:424-438.
12. Zechner D, Thuerauf DJ, Hanford DS, McDonough PM, Glembotski CC. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol. 1997;139:115-127.
13. Wang Y, Huanf S, Sah VP, Ross J, Heller Brown J, Han J, Chien KR. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 1998;273:2161-2168.
14. 2-terminal kinase in ventricular muscle cells. J Biol Chem. 1998;272:5423-5426.
15. Molkentin JD, Lu JR, Amos CL, Markham B, Richardson J, Robbins J. Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
16. Rao A, Luo C, Hogan PG. Transcription factors of the NF-AT family: regulation and function. Annu Rev Immunol. 1997;15:707-747.
17. Klee CB, Ren H, Wang X. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem. 1998;273:13367-13370.
18. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, Molkentin JD. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998;281:1690-1693.
19. Luo Z, Shyu KG, Gualberto A, Walsh K. Calcineurin and cardiac hypertrophy. Nat Med. 1998;10:1092-1093.
20. Müller JG. Nemoto S, Laser M, Carabello BA, Menick DR. Calcineurin inhibition and cardiac hypertrophy. Science. 1998;282:1007. Letter.
21. Zhang W, Kowal RC, Rusnak F, Sikkink RA, Olson EN, Victor RG. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res. 1999;84:722-728.
22. Ding B, Price RL, Borg TK, Weinberg EO, Halloran PF, Lorell BH. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res. 1999;84:729-734.
23. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, Vatner SF. Cyclosporine attenuates pressure overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res. 1999;84:735-740.
24. Goodman NM, Lowell B, Belur E, Ruderman NB. Sites of protein conservation and loss during starvation: influence of adiposity. Am J
25. Emsberger P, Koletsky RJ, Baskin JS, Collins LA. Consequences of weight cycling in obese spontaneously hypertensive rats. Am J Physiol. 1996;270:R864-R872.
26. Jones WK, Grupp IL, Doetschman T, Grupp G, Osinska H, Hewett T, Boivin G, Gulick J, Ng WA, Robbins J. Ablation of the murine α myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J Clin Invest. 1996;98:1906-1917.
27. Maier LS, Brandes R, Pieske B, Bers DM. Effects of left ventricular hypertrophy on force and Ca2+ handling in isolated rat myocardium. Am J Physiol. 1998;274:H1361-H1370.
28. Dolber PC, Bauman RP, Rembert JC, Greenfield JR. Regional changes in myocyte structure in model of canine right atrial hypertrophy. Am J Physiol. 1994;267:H1279-H1287.
29. Parke J, Charles BG. NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. Ther Drug Monit. 1998;20:284-294.
30. Batiuk TD, Urmson J, Vincent D, Yatscoff RW, Halloran PF. Quantitating immunosuppression. Transplantation. 1996;61:1618-1624.
31. Clipstone NA, Fiorentino DF, Crabtree GR. Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes. J Biol Chem. 1994;269:26431-26437.
32. Ventura HO, Malik FS, Mehra MR, Stapelton DD, Smart FW. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol. 1997;12:375-381.
33. Atkison P, Joubert G, Barron A, Grant D, Paradis K, Seidman E, Wall W, Rosenberg H, Howard J, Williams S, Stiller C. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet. 1995;345:894-896.
34. Chang RK, Alzona M, Alejos J, Jue K, McDiarmid SV. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. Am J Cardiol. 1998:81:1277-1280. Physiol. 1984;246:E383-E390.
35. Chang RK, Alzona M, Alejos J, Jue K, McDiarmid SV. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. Am J Cardiol. 1998:81:1277-1280. Physiol. 1984;246:E383-E390.